While guidelines endorse the use of PCSK9 inhibitors in patients at very high and high risk of cardiovascular events, real-world use is still far from optimal. Two new studies highlight the high burden of preventable cardiovascular events in routine practice.
From the USA »
From Denmark »
BANTING STUDY now published – Professor Robert Rosenson gives his interpretation
Watch the video here »
Other picks from the PCSK9 Forum experts include:
| 
